1. Academic Validation
  2. BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent

BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent

  • Bioorg Med Chem Lett. 2015 May 1;25(9):1905-9. doi: 10.1016/j.bmcl.2015.03.038.
Weifang Shan 1 Aaron Balog 2 Claude Quesnelle 2 Patrice Gill 2 Wen-Ching Han 2 Derek Norris 2 Sunilkumar Mandal 3 Raja Thiruvenkadam 3 Kiran Babu Gona 3 Kamalraj Thiyagarajan 3 Sathiah Kandula 3 Kelly McGlinchey 2 Krista Menard 2 Mei-Li Wen 2 Anne Rose 2 Ronald White 2 Victor Guarino 2 Ding Ren Shen 2 Mary Ellen Cvijic 2 Asoka Ranasinghe 2 Jun Dai 2 Yingru Zhang 2 Dauh-Rurng Wu 2 Arvind Mathur 2 Richard Rampulla 2 George Trainor 2 John T Hunt 2 Gregory D Vite 2 Richard Westhouse 2 Francis Y Lee 2 Ashvinikumar V Gavai 2
Affiliations

Affiliations

  • 1 Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States. Electronic address: weifang.shan@bms.com.
  • 2 Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States.
  • 3 Biocon BMS Research and Development Center (BBRC), Syngene International Ltd, Plot No. 2 & 3, Bommasandra IV Phase, Jigani Link Road, Bangalore 560 099, India.
Abstract

This Letter describes synthesis, SAR, and biological activity of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides as inhibitors of γ-secretase mediated signaling of Notch receptors. Optimization of this series led to the identification of BMS-871 (compound 30) which displayed robust in vivo efficacy in Notch-dependent leukemia and solid tumor xenograft models.

Keywords

Anticancer; Notch inhibitor; T-acute lymphoblastic leukemia; Triple-negative breast cancer.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-120372
    泛Notch抑制剂